The American Journal of Managed Care10d
Psoriasis Treatment Remains Effective, Safe After Switch From Ustekinumab to Biosimilar SB17
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...
JD Supra8d
Competition Tribunal refuses JAMP leave to commence ustekinumab abuse of dominance application
As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...
The American Journal of Managed Care10d
Ustekinumab Biosimilar Launches in France, Shifts the Autoimmune Disease Market
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
JD Supra1mon
FDA Approves Celltrion’s STEQEYMA (ustekinumab-stba)
On December 18, 2024, Celltrion announced that the FDA has approved its ustekinumab biosimilar, STEQEYMA (ustekinumab-stba), referencing Jannsen’s STELARA. STEQEYMA is approved for subcutaneous ...